{"gene":"TCIRG1","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":1999,"finding":"Targeted disruption of Atp6i (TCIRG1/a3 subunit of vacuolar proton pump) in mice results in severe osteopetrosis. Atp6i-/- osteoclast-like cells lose extracellular acidification function but retain intracellular lysosomal proton pump activity. pH in Atp6i-/- liver lysosomes and proton transport in microsomes of Atp6i-/- kidney are identical to wild-type, demonstrating that Atp6i is uniquely and specifically required for osteoclast-mediated extracellular acidification.","method":"Targeted gene disruption (knockout mouse), extracellular acidification assay, lysosomal pH measurement, microsome proton transport assay","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — clean knockout with multiple orthogonal functional assays demonstrating compartment-specific proton pump requirement","pmids":["10581033"],"is_preprint":false},{"year":2000,"finding":"TCIRG1, encoding the osteoclast-specific 116-kDa subunit (a3) of the vacuolar proton pump, is mutated in human autosomal recessive osteopetrosis patients. Osteoclasts are present in normal or elevated numbers, indicating the defect is in functional capacity (acidification) rather than osteoclast differentiation.","method":"Mutation analysis (DNA sequencing), patient cohort genotyping","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic causation established in human patients, replicated across multiple labs and extended in subsequent studies","pmids":["10888887"],"is_preprint":false},{"year":2003,"finding":"In vitro-differentiated osteoclasts from TCIRG1 compound heterozygous patients attach to bone and undergo cell fusion but fail to acidify attachment sites, consistent with TCIRG1 being essential for H+-ATPase assembly at the ruffled border. CLCN7-deficient osteoclasts, by contrast, do secrete acid but have defective organic matrix removal, distinguishing the two proteins' roles.","method":"In vitro osteoclast differentiation from CD14+ monocytes, acid secretion assay, bone pitting assay, enzyme assays, attachment protein assays","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional assays on patient-derived cells with genotype correlation, multiple orthogonal readouts","pmids":["15231021"],"is_preprint":false},{"year":2003,"finding":"Bone biopsies from TCIRG1-mutant osteopetrosis patients show osteoclasts that are morphologically normal (actin rings, clear zones, podosomes, normal alphavbeta3, c-Src, PYK2) and TRAP-positive, but are a3-subunit-negative and excavate only faint, shallow pits, indicating inefficient bone resorption due to absent proton pump subunit. Post-bone marrow transplant osteoclasts rescue a3 subunit immunoreactivity.","method":"Bone biopsy analysis, immunohistochemistry, in vitro osteoclast differentiation, bone resorption pit assay, TRAP activity assay","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional and morphological characterization of patient osteoclasts with genotype-phenotype correlation and transplant rescue","pmids":["12507890"],"is_preprint":false},{"year":2003,"finding":"Electron microscopy of bone biopsies from a TCIRG1-mutant osteopetrosis infant showed osteoclasts lacking ruffled borders. Post-transplant donor osteoclasts had ruffled borders and intracytoplasmic mineral crystals, demonstrating active bone resorption restored by donor TCIRG1-expressing osteoclasts.","method":"Electron microscopy of bone biopsies pre- and post-bone marrow transplantation","journal":"Pediatric pathology & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — electron microscopy with transplant rescue, single case report","pmids":["12687885"],"is_preprint":false},{"year":1998,"finding":"TIRC7 (an alternative transcript product of the TCIRG1 locus) functions as a membrane protein essential for T cell activation. Anti-TIRC7 antibodies prevent human T cell proliferation and IL-2 secretion in vitro, specifically inhibit IFN-gamma (Th1) but not IL-4 (Th2) expression, and prolong kidney allograft survival in vivo via inhibition of rat alloimmune response.","method":"In vitro T cell proliferation assay, cytokine secretion assay, rat kidney allograft transplantation model, anti-TIRC7 antibody modulation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro and in vivo functional experiments with antibody intervention, replicated across multiple subsequent studies","pmids":["9806637"],"is_preprint":false},{"year":1999,"finding":"TIRC7 and OC116 (TCIRG1) are alternative transcripts of the same gene on chromosome 11q13.4-q13.5, with TIRC7 consisting of 15 exons and OC116 of 20 exons sharing the last 14 introns and exons. In human alloactivated T lymphocytes, only TIRC7 (not OC116) mRNA is expressed, indicating transcript-specific expression patterns.","method":"Genomic cloning, exon-intron boundary analysis, RT-PCR in alloactivated T lymphocytes","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct genomic characterization with functional validation of differential expression; confirmed by multiple subsequent studies","pmids":["10329006"],"is_preprint":false},{"year":2004,"finding":"TIRC7-deficient (knockout) mice exhibit increased T and B cell proliferation, elevated IL-2, IFN-gamma, and IL-4, expansion of memory/effector T cells (decreased CD62L, increased CD11a/CD44), decreased CTLA-4 expression in activated T cells, B cell hyperreactivity, and augmented delayed-type hypersensitivity. This establishes TIRC7 as a negative regulator of both T and B cell responses.","method":"Gene targeting (knockout mouse), in vitro T and B cell proliferation assays, cytokine expression assays, flow cytometry, delayed-type hypersensitivity model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout mouse with multiple orthogonal in vitro and in vivo functional readouts","pmids":["15294947"],"is_preprint":false},{"year":2006,"finding":"Anti-TIRC7 antibody targeting induces early cell surface expression of CTLA-4. TIRC7 co-localizes with CTLA-4 and both accumulate at the site of antigen adhesion upon T cell activation. Both are associated with clathrin-coated vesicles, indicating shared intracellular transport. Anti-TIRC7-mediated inhibition of T cell proliferation is abolished by anti-CTLA-4 antibody blockade, and CTLA-4-deficient mouse splenocytes are not responsive to TIRC7 antibody. Thus TIRC7 acts upstream of CTLA-4.","method":"Flow cytometry, immunofluorescence co-localization, CTLA-4 transcription activation assay, anti-CTLA-4 blockade rescue experiments, CTLA-4 knockout mouse splenocytes","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods establishing epistatic relationship between TIRC7 and CTLA-4, including genetic rescue with CTLA-4 KO","pmids":["17082597"],"is_preprint":false},{"year":2008,"finding":"HLA-DR alpha2 domain (sHLA-DRalpha2) binds TIRC7 on lymphocytes, inducing negative signaling: inhibition of proliferation, apoptosis of CD4+ and CD8+ T cells via intrinsic pathway, SHP-1 recruitment by TIRC7, decreased phosphorylation of STAT4, TCR-zeta chain and ZAP70, inhibition of IFN-gamma and FasL. HLA-DRalpha2 and TIRC7 co-localize at the APC-T cell interaction site.","method":"Co-localization by microscopy, SHP-1 recruitment assay, phosphorylation assays (STAT4, TCR-zeta, ZAP70), cytokine expression assays, apoptosis assays, LPS stimulation in vitro, in vivo apoptosis assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — binding partner identified, downstream signaling cascade characterized with multiple orthogonal methods","pmids":["18270567"],"is_preprint":false},{"year":2010,"finding":"In Tcirg1-/- (a3-deficient) mice, the a3 subunit accumulates in the choriocapillary meshwork in uveal tissues, while a4 subunit expression is increased in the choriocapillary meshwork of mutant mice (compensatory upregulation). Narrowed foramina in the skull (demonstrated by X-ray microtomography) cause optic nerve compression with increased retinal apoptosis, despite normal retinal architecture.","method":"X-ray microtomography, immunohistochemistry for V-ATPase subunit localization, apoptosis assay (retina), Tcirg1-/- mice","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct localization and functional consequence in KO mice, single study with multiple methods but limited replication","pmids":["20711468"],"is_preprint":false},{"year":2012,"finding":"Murine maturation-stage ameloblasts are immunonegative for Tcirg1 (a3 subunit), despite expressing V-ATPase subunit b (brain isoform). In Tcirg1 null (oc/oc) mice, enamel formation is normal and ameloblasts are unaffected, demonstrating that the a3 subunit is not required for ameloblast proton pump activity and that a different V-ATPase isoform functions there.","method":"Immunohistochemistry, Tcirg1 null mouse analysis, enamel mineral content analysis","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct immunolocalization and functional characterization in KO mice, single study","pmids":["22245629"],"is_preprint":false},{"year":2013,"finding":"Lentiviral gene transfer of TCIRG1 into peripheral blood CD34+ cells from TCIRG1-deficient osteopetrosis patients restored osteoclast resorptive function in vitro, as measured by increased Ca2+ release, CTX-I bone degradation product, and resorption pit formation on bone slices. Non-corrected patient osteoclasts failed to resorb bone.","method":"Lentiviral gene transfer, in vitro osteoclast differentiation on bone slices, qPCR, western blot, Ca2+ release assay, CTX-I ELISA, resorption pit assay, NSG mouse engraftment","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Strong — gene correction with multiple functional readouts, multiple patient samples, in vivo engraftment demonstrated","pmids":["23907031"],"is_preprint":false},{"year":2013,"finding":"AAV-mediated RNAi knockdown of Atp6i/TIRC7 in periodontal tissues impairs extracellular acidification and osteoclast-mediated bone resorption, protecting mice from P. gingivalis infection-stimulated bone loss (>85% reduction) and decreasing T-cell infiltration. Atp6i haploinsufficient mice (Atp6i+/-) show similar protection from bone resorption and inflammation.","method":"AAV-shRNA knockdown in vivo, P. gingivalis infection model, bone resorption measurement, T-cell quantification, cytokine gene expression analysis, Atp6i+/- haploinsufficiency comparison","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gene knockdown and haploinsufficiency model with multiple orthogonal readouts","pmids":["23577057"],"is_preprint":false},{"year":2013,"finding":"AAV-mediated Atp6i RNAi knockdown in periapical tissues inhibits osteoclast function in vitro and in vivo, reduces T-cell numbers in periapical lesions, and reduces bacterial infection-stimulated periapical bone resorption by ~80%. Atp6i+/- haploinsufficient mice show similar protection.","method":"AAV-shRNA knockdown, endodontic disease mouse model, in vitro osteoclast function assay, T-cell quantification, bone resorption measurement","journal":"Infection and immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gene knockdown with haploinsufficiency confirmation and multiple functional readouts","pmids":["23166162"],"is_preprint":false},{"year":2014,"finding":"TCIRG1 mutations cause severe osteoid accumulation (osteomalacia) in osteopetrosis patients, whereas CLCN7 and TNFRSF11A mutations do not. Undecalcified bone biopsies from TCIRG1-mutant patients show pathological osteoid increase and decreased calcium content in mineralized matrix, revealing a specific role of TCIRG1/a3-mediated acidification in bone matrix mineralization.","method":"Undecalcified iliac crest bone biopsy histology, quantitative bone histomorphometry, serum calcium measurement","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct bone histology in multiple patients with genotype-phenotype comparison across three gene groups","pmids":["24108692"],"is_preprint":false},{"year":2014,"finding":"TCIRG1 heterozygous mutations (including R736S, identified in a large pedigree) cause severe congenital neutropenia with reduced TCIRG1 protein levels in affected individuals (western blot). This establishes that TCIRG1 dysfunction impairs not only osteoclast but also neutrophil function.","method":"Western blot (reduced protein in affected individuals), family segregation analysis, DNA sequencing","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — protein reduction confirmed by western blot, perfect family cosegregation, but mechanistic detail is limited","pmids":["24753205"],"is_preprint":false},{"year":2016,"finding":"Lentiviral vector-mediated TCIRG1 expression in osteoclasts is post-transcriptionally regulated, being detected only in mature osteoclasts (not precursors or macrophages) despite GFP being expressed in all cell types from the same bicistronic vector. Codon optimization increases mRNA but decreases protein levels and functional rescue. Addition of 30% wild-type CD34+ cells to TCIRG1-deficient cells is sufficient to completely normalize resorptive function in vitro.","method":"Lentiviral gene transfer, qPCR, western blot, in vitro osteoclast differentiation, resorption assay, GFP reporter comparison","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple assays in a single study establishing post-transcriptional regulation mechanism and functional threshold","pmids":["27541021"],"is_preprint":false},{"year":2019,"finding":"A novel TCIRG1 mutation (c.G630A) causes aberrant splicing producing exon 5-6 deletion (ΔE56). The ΔE56-truncated protein (lacking part of the cytoplasmic N-terminal domain) fails to complement V-ATPase function in yeast (fails to grow on Zn2+-containing plates requiring vacuolar acidification), while the full-length protein does. This demonstrates the N-terminal cytoplasmic domain (encoded by exons 5-6) is required for V-ATPase function.","method":"Splice assay, yeast complementation assay (Vph1p ortholog), in vitro osteoclast differentiation from patient monocytes, bone resorption pit assay, TCIRG1 protein/mRNA expression analysis","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — yeast reconstitution assay combined with patient cell functional assays and mutation characterization","pmids":["31111556"],"is_preprint":false},{"year":2019,"finding":"TCIRG1 transgenic expression in iPSC-derived osteoclasts from a compound heterozygous TCIRG1 patient restored bone-resorbing function (pit formation), and also rescued reduced expression of cathepsin K (CTSK) and tartrate-resistant acid phosphatase (TRAP). This demonstrates that TCIRG1 loss reduces not only proton pump activity but also expression of downstream bone remodeling enzymes.","method":"iPSC generation and osteoclast differentiation, transgenic TCIRG1 expression, pit formation assay, gene expression analysis (CTSK, TRAP), western blot","journal":"The Journal of bone and joint surgery. American volume","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — iPSC-derived osteoclasts with transgenic rescue, multiple functional readouts, single study","pmids":["31567691"],"is_preprint":false},{"year":2020,"finding":"Knockdown of Tcirg1 in mouse bone marrow-derived monocytes inhibits large osteoclast (>100 μm) generation by decreasing expression of NFATc1 and IP3R2. Reduced IP3R2 lowers intracellular calcium levels, which limits nuclear translocation of NFATc1 in RANKL-induced osteoclastogenesis.","method":"Lentiviral Tcirg1 knockdown in BMMs, osteoclast differentiation assay, NFATc1/IP3R2 expression analysis, intracellular calcium measurement, nuclear translocation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with mechanistic pathway characterization (NFATc1/IP3R2/Ca2+), single lab study","pmids":["32790690"],"is_preprint":false},{"year":2023,"finding":"Atp6i-/- (TCIRG1-deficient) mice exhibit arrested tooth root formation with truncated Hertwig's epithelial root sheath progression and reduced odontoblast differentiation. Conditioned medium from wild-type osteoclasts (but not Atp6i-/- osteoclasts) promotes odontoblast differentiation via TGF-β1/Smad2/3 signaling. Anti-TGF-β1 neutralization blocks this effect. Ectopic TGF-β1 partially rescues root development in Atp6i-/- tooth germ transplants, establishing TGF-β1 release from bone matrix (dependent on TCIRG1-mediated osteoclast acidification) as a key pathway for odontoblast differentiation and tooth root formation.","method":"Atp6i-/- mouse analysis, conditioned medium experiments, anti-TGF-β1 neutralization, Smad2/3 activation assay, RNA-seq, kidney capsule tooth germ transplant rescue, immunohistochemistry","journal":"International journal of oral science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including KO mouse, conditioned medium, neutralization, and in vivo rescue experiments establishing TGF-β1/Smad2/3 pathway downstream of TCIRG1","pmids":["37599332"],"is_preprint":false},{"year":2025,"finding":"Tcirg1 deficiency in osteoclasts impairs lysosome acidification and peripheral (plasma membrane) accumulation of lysosomes, thereby inhibiting osteoclast fusion and bone resorption. Tcirg1-knockout mice show delayed OA progression with reduced subchondral bone loss and cartilage damage.","method":"Tcirg1 knockout mouse OA model (destabilization of medial meniscus), histology, micro-CT, in vitro osteoclast differentiation assay, lysosome acidification assay, lysosome distribution analysis","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with in vitro mechanistic follow-up on lysosome biology, single lab study","pmids":["40995561"],"is_preprint":false},{"year":2025,"finding":"CRISPR/Cas9-mediated correction of the R736C TCIRG1 mutation in patient-derived iPSCs restored normal neutrophil differentiation. Mutant iPSC lines showed reduced TCIRG1 protein expression and altered intracellular localization (more diffuse cytosolic distribution), suggesting structural and functional disruption of the V-ATPase complex underlies impaired granulopoiesis.","method":"iPSC generation from patients, CRISPR/Cas9 correction, in vitro hematopoietic differentiation, immunofluorescence for TCIRG1 localization, proliferation and survival assays","journal":"Journal of cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR rescue with localization and functional assays, single lab study","pmids":["40964614"],"is_preprint":false},{"year":2024,"finding":"VMA21 binds TCIRG1 protein and inhibits its ubiquitination-mediated degradation, thereby stabilizing TCIRG1 protein expression in triple-negative breast cancer cells. VMA21 knockdown reduces TCIRG1 protein levels and impairs TNBC cell proliferation, invasion, and immune evasion.","method":"Immunoprecipitation (VMA21-TCIRG1 interaction), ubiquitination assay, VMA21 knockdown, western blot, cell proliferation/invasion/migration assays, CD8+ T cell co-culture assay","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and ubiquitination assay establish interaction and regulatory mechanism, single lab study in cancer context","pmids":["39267677"],"is_preprint":false},{"year":2012,"finding":"The C-terminal extracellular peptide of Tirc7 (the T-cell-expressed TCIRG1 transcript) induces differentiation of RAW264.7 cells and mouse bone marrow CD11b+ cells into osteoclast-like multinucleated TRACP-positive cells, and induces an autocrine/paracrine regulatory loop in osteoclast precursors. Primary monocytes treated with Tirc7-Cter peptide form small multinucleated cells with dendritic cell marker modulation but lacking resorbing activity.","method":"Molecular cloning of Tirc7 C-terminal peptide, treatment of RAW264.7 and bone marrow-derived precursor cells, TRACP staining, F4/80 expression analysis, resorption activity assay","journal":"Journal of cellular physiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, peptide-based experiment with partial mechanistic follow-up, no genetic confirmation","pmids":["22015593"],"is_preprint":false}],"current_model":"TCIRG1 encodes the a3 subunit of the vacuolar H+-ATPase (V-ATPase), which is essential for osteoclast-mediated extracellular acidification at the bone resorption lacuna (ruffled border); loss of TCIRG1 specifically abolishes extracellular acidification while preserving intracellular lysosomal V-ATPase activity, causing severe osteopetrosis. The same gene locus produces an alternative transcript (TIRC7) in T lymphocytes that negatively regulates T and B cell activation by acting upstream of CTLA-4 (inducing its surface expression and transcription) and by transducing inhibitory signals upon engagement by HLA-DR alpha2 via SHP-1 recruitment and reduced STAT4/ZAP70/TCR-zeta phosphorylation. In osteoclasts, TCIRG1 also regulates lysosome acidification and peripheral lysosome accumulation required for osteoclast fusion and bone resorption, controls NFATc1 nuclear translocation via IP3R2-dependent calcium oscillations, and enables TGF-β1 release from bone matrix that drives odontoblast differentiation via Smad2/3 signaling; TCIRG1 protein stability in cancer cells is regulated by VMA21, which prevents its ubiquitination-mediated degradation."},"narrative":{"mechanistic_narrative":"TCIRG1 encodes the osteoclast-specific 116-kDa a3 subunit of the vacuolar H+-ATPase (V-ATPase), and is uniquely required for osteoclast-mediated extracellular acidification at the bone-resorption surface while being dispensable for intracellular lysosomal proton-pump activity in other tissues [PMID:10581033]. Loss of TCIRG1 causes severe autosomal recessive osteopetrosis in humans: osteoclasts are present in normal or elevated numbers and attach to bone with intact actin rings and podosomes, but lack ruffled borders, fail to acidify their attachment sites, and excavate only shallow pits — establishing the defect as functional rather than developmental [PMID:10888887, PMID:15231021, PMID:12507890]. The a3 N-terminal cytoplasmic domain (encoded by exons 5–6) is required for V-ATPase function, as the corresponding truncation fails to complement vacuolar acidification in yeast [PMID:31111556]. Beyond proton transport per se, TCIRG1-dependent acidification drives downstream osteoclast biology: it controls lysosome acidification and peripheral lysosome accumulation needed for cell fusion and resorption [PMID:40995561], supports NFATc1 nuclear translocation through IP3R2-dependent calcium signaling during RANKL-induced osteoclastogenesis [PMID:32790690], enables release of matrix TGF-β1 that drives odontoblast differentiation and tooth-root formation via Smad2/3 signaling [PMID:37599332], and is required for matrix mineralization, with TCIRG1 mutation producing osteoid accumulation not seen with CLCN7 or TNFRSF11A defects [PMID:24108692]. Restoration of TCIRG1 by lentiviral, transgenic, or CRISPR-corrected approaches rescues resorptive function and downstream enzyme expression (cathepsin K, TRAP) in patient-derived osteoclasts [PMID:23907031, PMID:31567691]. The same locus produces an alternative transcript, TIRC7, expressed in activated lymphocytes rather than the osteoclast OC116 form [PMID:10329006]; TIRC7 acts as a negative regulator of T and B cell activation, functioning upstream of CTLA-4 to induce its expression and transducing inhibitory signals upon engagement by HLA-DR alpha2 via SHP-1 recruitment and reduced STAT4/ZAP70/TCR-zeta phosphorylation [PMID:15294947, PMID:17082597, PMID:18270567]. TCIRG1 mutations also cause severe congenital neutropenia through impaired neutrophil/granulopoiesis function [PMID:24753205, PMID:40964614], and TCIRG1 protein in cancer cells is stabilized by VMA21, which blocks its ubiquitination-mediated degradation [PMID:39267677].","teleology":[{"year":1999,"claim":"Resolved whether the a3 subunit serves a general or compartment-specific proton-pump role, showing it is uniquely required for osteoclast extracellular acidification but not lysosomal acidification elsewhere.","evidence":"Atp6i knockout mice with extracellular acidification, lysosomal pH, and microsome proton-transport assays","pmids":["10581033"],"confidence":"High","gaps":["Does not identify which alternative a-subunit isoforms maintain lysosomal V-ATPase activity in TCIRG1-null cells","Molecular basis for the osteoclast-specific requirement not defined"]},{"year":2000,"claim":"Established TCIRG1 as a genetic cause of human autosomal recessive osteopetrosis, localizing the defect to osteoclast acidification capacity rather than osteoclast number.","evidence":"Mutation analysis and genotyping of human osteopetrosis patient cohort","pmids":["10888887"],"confidence":"High","gaps":["Does not establish the structural consequence of individual mutations","Fraction of osteopetrosis attributable to TCIRG1 versus other loci not addressed here"]},{"year":2003,"claim":"Showed that TCIRG1-deficient osteoclasts complete attachment and fusion but fail to acidify and form ruffled borders, distinguishing the TCIRG1 acidification defect from the matrix-degradation defect of CLCN7.","evidence":"Patient-derived in vitro osteoclasts, bone biopsies, immunohistochemistry, EM, acid-secretion and pit assays, with transplant rescue","pmids":["15231021","12507890","12687885"],"confidence":"High","gaps":["Does not define how the a3 subunit is targeted to and assembled at the ruffled border","Mechanism linking acidification loss to ruffled-border absence not resolved"]},{"year":1998,"claim":"Identified TIRC7 as a lymphocyte-expressed product of the TCIRG1 locus essential for T cell activation, with antibody targeting selectively suppressing Th1 responses and prolonging allograft survival.","evidence":"Anti-TIRC7 antibody modulation in human T cell proliferation/cytokine assays and a rat kidney allograft model","pmids":["9806637"],"confidence":"High","gaps":["Antibody-based readouts do not define the endogenous ligand or receptor partner at this stage","Relationship of TIRC7 to the osteoclast a3 protein not yet established"]},{"year":1999,"claim":"Demonstrated that TIRC7 and OC116/TCIRG1 are alternative transcripts of one locus with tissue-restricted expression, explaining how a single gene yields both an immune regulator and an osteoclast proton-pump subunit.","evidence":"Genomic cloning, exon-intron mapping, and RT-PCR in alloactivated T lymphocytes","pmids":["10329006"],"confidence":"High","gaps":["Transcriptional control of the isoform switch not defined","Whether the two protein products share any functional domains in their respective contexts not addressed"]},{"year":2004,"claim":"Established TIRC7 as a negative regulator of both T and B cell responses through loss-of-function genetics, linking it to control of CTLA-4 expression and memory/effector differentiation.","evidence":"TIRC7 knockout mice with proliferation, cytokine, flow-cytometry and delayed-type hypersensitivity assays","pmids":["15294947"],"confidence":"High","gaps":["Does not establish the molecular signaling intermediates downstream of TIRC7","Mechanism connecting TIRC7 to CTLA-4 not yet defined"]},{"year":2006,"claim":"Placed TIRC7 epistatically upstream of CTLA-4, showing it induces CTLA-4 surface expression and that its inhibitory action requires CTLA-4.","evidence":"Flow cytometry, immunofluorescence co-localization, anti-CTLA-4 blockade rescue, and CTLA-4 knockout splenocytes","pmids":["17082597"],"confidence":"High","gaps":["Does not identify the receptor/ligand that triggers TIRC7 signaling","Mechanism of clathrin-coated-vesicle co-trafficking with CTLA-4 not detailed"]},{"year":2008,"claim":"Identified HLA-DR alpha2 as a TIRC7 binding partner that triggers an inhibitory signaling cascade, defining the receptor-proximal mechanism of TIRC7-mediated lymphocyte suppression.","evidence":"Co-localization, SHP-1 recruitment, phospho-STAT4/TCR-zeta/ZAP70 assays, apoptosis and cytokine assays","pmids":["18270567"],"confidence":"High","gaps":["Stoichiometry and structural basis of the HLA-DRalpha2–TIRC7 interaction not resolved","How a V-ATPase-related transcript transduces a phosphatase-recruiting signal mechanistically unclear"]},{"year":2013,"claim":"Demonstrated therapeutic restorability of osteoclast function and showed Atp6i targeting protects against infection-driven bone loss, validating TCIRG1 acidification as both a corrigible defect and a drug target.","evidence":"Lentiviral TCIRG1 gene transfer into patient CD34+ cells with resorption readouts; AAV-RNAi knockdown and haploinsufficiency in periodontal and periapical infection models","pmids":["23907031","23577057","23166162"],"confidence":"High","gaps":["Does not define the minimal expression level for durable in vivo correction","Whether reduced T-cell infiltration is a direct or secondary consequence of acidification loss not separated"]},{"year":2014,"claim":"Expanded the TCIRG1 phenotypic spectrum to matrix mineralization and to neutrophil biology, showing TCIRG1 loss causes osteoid accumulation distinct from other osteopetrosis genes and underlies a form of severe congenital neutropenia.","evidence":"Undecalcified bone histomorphometry across gene groups; family segregation with western-blot confirmation of reduced TCIRG1 protein","pmids":["24108692","24753205"],"confidence":"Medium","gaps":["Mechanism linking acidification to mineralization versus osteoid build-up not resolved","How heterozygous TCIRG1 dysfunction specifically impairs granulopoiesis not mechanistically defined"]},{"year":2019,"claim":"Mapped a required functional element to the exon 5–6-encoded N-terminal cytoplasmic domain and confirmed transgenic rescue, connecting a specific splice/structural defect to loss of V-ATPase activity.","evidence":"Splice assay, yeast Vph1p complementation, and TCIRG1 transgenic rescue in iPSC-derived patient osteoclasts with enzyme-expression readouts","pmids":["31111556","31567691"],"confidence":"High","gaps":["Full domain architecture and assembly requirements of the a3 subunit not delineated","Why TCIRG1 loss reduces downstream CTSK/TRAP expression not mechanistically explained"]},{"year":2020,"claim":"Linked TCIRG1 to an osteoclastogenic signaling axis, showing its loss reduces IP3R2-dependent calcium and NFATc1 nuclear translocation, implicating TCIRG1 in regulation beyond direct proton transport.","evidence":"Lentiviral Tcirg1 knockdown in BMMs with NFATc1/IP3R2 expression, calcium measurement, and nuclear-translocation assays","pmids":["32790690"],"confidence":"Medium","gaps":["Single-lab study without genetic rescue of the calcium/NFATc1 phenotype","Whether the effect is downstream of acidification loss or an independent function unclear"]},{"year":2023,"claim":"Established TCIRG1-dependent osteoclast acidification as the upstream event releasing matrix TGF-β1 to drive odontoblast differentiation and tooth-root formation via Smad2/3.","evidence":"Atp6i knockout mice, conditioned-medium experiments, anti-TGF-β1 neutralization, Smad2/3 assays, and in vivo tooth-germ transplant rescue","pmids":["37599332"],"confidence":"High","gaps":["Quantitative contribution of matrix TGF-β1 versus other osteoclast-derived factors not separated","Direct demonstration that acidification per se liberates TGF-β1 not provided"]},{"year":2024,"claim":"Identified a post-translational regulator of TCIRG1, showing VMA21 stabilizes the protein by preventing its ubiquitination-mediated degradation in cancer cells.","evidence":"VMA21-TCIRG1 co-immunoprecipitation, ubiquitination assay, VMA21 knockdown with proliferation/invasion and CD8+ T cell co-culture assays","pmids":["39267677"],"confidence":"Medium","gaps":["Single-lab Co-IP without reciprocal validation of the interaction interface","Ubiquitin ligase responsible for TCIRG1 turnover not identified"]},{"year":2025,"claim":"Refined the cellular mechanism of TCIRG1 in osteoclast fusion and granulopoiesis, linking it to lysosome acidification/peripheral distribution and to proper TCIRG1 localization within the V-ATPase complex.","evidence":"Tcirg1 knockout mouse OA model with lysosome acidification/distribution assays; CRISPR correction of R736C in patient iPSCs with neutrophil differentiation and localization readouts","pmids":["40995561","40964614"],"confidence":"Medium","gaps":["Single-lab studies without orthogonal confirmation of the lysosome-distribution mechanism","How mislocalized mutant TCIRG1 disrupts V-ATPase assembly structurally not resolved"]},{"year":null,"claim":"How a single locus coordinates expression of the osteoclast a3 V-ATPase subunit versus the immunoregulatory TIRC7 transcript, and how TIRC7 mechanistically couples to phosphatase-based inhibitory signaling, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of the a3 subunit within the assembled osteoclast V-ATPase","Regulatory logic of the OC116/TIRC7 isoform switch undefined","Mechanistic link between V-ATPase function and downstream NFATc1/TGF-β1 signaling not fully separated from acidification"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,2,18]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,18]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[8,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,22]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0,22]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[23]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,2,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,7,8,9]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[2,15,21]}],"complexes":["vacuolar H+-ATPase (V-ATPase)"],"partners":["VMA21","CTLA4","HLA-DRA","SHP-1","IP3R2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13488","full_name":"V-type proton ATPase 116 kDa subunit a 3","aliases":["Osteoclastic proton pump 116 kDa subunit","OC-116 kDa","OC116","T-cell immune regulator 1","T-cell immune response cDNA7 protein","TIRC7","Vacuolar proton translocating ATPase 116 kDa subunit a isoform 3"],"length_aa":830,"mass_kda":93.0,"function":"Subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (By similarity). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity). Seems to be directly involved in T-cell activation (PubMed:10329006)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q13488/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TCIRG1","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TCIRG1","total_profiled":1310},"omim":[{"mim_id":"615198","title":"OSTEOSCLEROTIC METAPHYSEAL DYSPLASIA; OSMD","url":"https://www.omim.org/entry/615198"},{"mim_id":"612301","title":"OSTEOPETROSIS, AUTOSOMAL RECESSIVE 7; OPTB7","url":"https://www.omim.org/entry/612301"},{"mim_id":"610986","title":"LEUCINE-RICH REPEAT KINASE 1; LRRK1","url":"https://www.omim.org/entry/610986"},{"mim_id":"607649","title":"OSTEOPETROSIS-ASSOCIATED TRANSMEMBRANE PROTEIN 1; OSTM1","url":"https://www.omim.org/entry/607649"},{"mim_id":"605239","title":"ATPase, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A, ISOFORM 4; ATP6V0A4","url":"https://www.omim.org/entry/605239"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"pancreas","ntpm":278.3}],"url":"https://www.proteinatlas.org/search/TCIRG1"},"hgnc":{"alias_symbol":["TIRC7","OC-116","OC116","ATP6N1C","Atp6i","a3","ATP6V0A3"],"prev_symbol":[]},"alphafold":{"accession":"Q13488","domains":[{"cath_id":"-","chopping":"18-107_278-312_327-347","consensus_level":"medium","plddt":88.0329,"start":18,"end":347},{"cath_id":"3.30.70.2750","chopping":"120-135_166-272","consensus_level":"medium","plddt":86.4167,"start":120,"end":272},{"cath_id":"-","chopping":"386-475_510-655_711-810","consensus_level":"medium","plddt":89.3697,"start":386,"end":810}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13488","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13488-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13488-F1-predicted_aligned_error_v6.png","plddt_mean":83.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TCIRG1","jax_strain_url":"https://www.jax.org/strain/search?query=TCIRG1"},"sequence":{"accession":"Q13488","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13488.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13488/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13488"}},"corpus_meta":[{"pmid":"10888887","id":"PMC_10888887","title":"Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10888887","citation_count":522,"is_preprint":false},{"pmid":"10581033","id":"PMC_10581033","title":"Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10581033","citation_count":382,"is_preprint":false},{"pmid":"15300850","id":"PMC_15300850","title":"TCIRG1-dependent recessive osteopetrosis: mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15300850","citation_count":85,"is_preprint":false},{"pmid":"12507890","id":"PMC_12507890","title":"Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12507890","citation_count":83,"is_preprint":false},{"pmid":"10329006","id":"PMC_10329006","title":"Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10329006","citation_count":67,"is_preprint":false},{"pmid":"9806637","id":"PMC_9806637","title":"Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein.","date":"1998","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9806637","citation_count":61,"is_preprint":false},{"pmid":"12552563","id":"PMC_12552563","title":"Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12552563","citation_count":47,"is_preprint":false},{"pmid":"24108692","id":"PMC_24108692","title":"CLCN7 and TCIRG1 mutations differentially affect bone matrix mineralization in osteopetrotic individuals.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24108692","citation_count":38,"is_preprint":false},{"pmid":"24753205","id":"PMC_24753205","title":"TCIRG1-associated congenital neutropenia.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24753205","citation_count":37,"is_preprint":false},{"pmid":"25829125","id":"PMC_25829125","title":"Buried in the Middle but Guilty: Intronic Mutations in the TCIRG1 Gene Cause Human Autosomal Recessive Osteopetrosis.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25829125","citation_count":36,"is_preprint":false},{"pmid":"22231430","id":"PMC_22231430","title":"Autosomal recessive osteopetrosis: report of 41 novel mutations in the TCIRG1 gene and diagnostic implications.","date":"2012","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/22231430","citation_count":35,"is_preprint":false},{"pmid":"23577057","id":"PMC_23577057","title":"RNAi-mediated silencing of Atp6i and Atp6i haploinsufficiency prevents both bone loss and inflammation in a mouse model of periodontal disease.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23577057","citation_count":34,"is_preprint":false},{"pmid":"19172990","id":"PMC_19172990","title":"Genetic analysis of autosomal recessive osteopetrosis in Chuvashiya: the unique splice site mutation in TCIRG1 gene spread by the founder effect.","date":"2009","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/19172990","citation_count":33,"is_preprint":false},{"pmid":"11295466","id":"PMC_11295466","title":"Monitoring of intragraft and peripheral blood TIRC7 expression as a diagnostic tool for acute cardiac rejection in humans.","date":"2001","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11295466","citation_count":29,"is_preprint":false},{"pmid":"23166162","id":"PMC_23166162","title":"RNA interference-mediated silencing of Atp6i prevents both periapical bone erosion and inflammation in the mouse model of endodontic disease.","date":"2013","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23166162","citation_count":29,"is_preprint":false},{"pmid":"15231021","id":"PMC_15231021","title":"In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects.","date":"2004","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/15231021","citation_count":28,"is_preprint":false},{"pmid":"31949009","id":"PMC_31949009","title":"Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/31949009","citation_count":25,"is_preprint":false},{"pmid":"15294947","id":"PMC_15294947","title":"TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15294947","citation_count":24,"is_preprint":false},{"pmid":"30537558","id":"PMC_30537558","title":"Sclerosing bone dysplasias with hallmarks of dysosteosclerosis in four patients carrying mutations in SLC29A3 and TCIRG1.","date":"2018","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/30537558","citation_count":22,"is_preprint":false},{"pmid":"14523594","id":"PMC_14523594","title":"Association between a polymorphism affecting an AP1 binding site in the promoter of the TCIRG1 gene and bone mass in women.","date":"2003","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/14523594","citation_count":22,"is_preprint":false},{"pmid":"17082597","id":"PMC_17082597","title":"TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17082597","citation_count":21,"is_preprint":false},{"pmid":"24535816","id":"PMC_24535816","title":"As little as needed: the extraordinary case of a mild recessive osteopetrosis owing to a novel splicing hypomorphic mutation in the TCIRG1 gene.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24535816","citation_count":21,"is_preprint":false},{"pmid":"20711468","id":"PMC_20711468","title":"Optic nerve compression and retinal degeneration in Tcirg1 mutant mice lacking the vacuolar-type H-ATPase a3 subunit.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20711468","citation_count":21,"is_preprint":false},{"pmid":"15023142","id":"PMC_15023142","title":"Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice.","date":"2004","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/15023142","citation_count":20,"is_preprint":false},{"pmid":"37649034","id":"PMC_37649034","title":"Glycolysis-related biomarker TCIRG1 participates in regulation of renal cell carcinoma progression and tumor immune microenvironment by affecting aerobic glycolysis and AKT/mTOR signaling pathway.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37649034","citation_count":20,"is_preprint":false},{"pmid":"35981697","id":"PMC_35981697","title":"Osteoclast rich osteopetrosis due to defects in the TCIRG1 gene.","date":"2022","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/35981697","citation_count":18,"is_preprint":false},{"pmid":"18648057","id":"PMC_18648057","title":"Ovocleidin (OC 116) is present in avian skeletal tissues.","date":"2008","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/18648057","citation_count":18,"is_preprint":false},{"pmid":"28816234","id":"PMC_28816234","title":"Novel mutations of TCIRG1 cause a malignant and mild phenotype of autosomal recessive osteopetrosis (ARO) in four Chinese families.","date":"2017","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/28816234","citation_count":18,"is_preprint":false},{"pmid":"12161516","id":"PMC_12161516","title":"Sibling pair linkage and association studies between peak bone mineral density and the gene locus for the osteoclast-specific subunit (OC116) of the vacuolar proton pump on chromosome 11p12-13.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12161516","citation_count":17,"is_preprint":false},{"pmid":"23907031","id":"PMC_23907031","title":"Lentiviral gene transfer of TCIRG1 into peripheral blood CD34(+) cells restores osteoclast function in infantile malignant osteopetrosis.","date":"2013","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/23907031","citation_count":17,"is_preprint":false},{"pmid":"18424726","id":"PMC_18424726","title":"Characterization of IL-10-secreting T cells derived from regulatory CD4+CD25+ cells by the TIRC7 surface marker.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18424726","citation_count":17,"is_preprint":false},{"pmid":"16542376","id":"PMC_16542376","title":"Antibody targeting of TIRC7 results in significant therapeutic effects on collagen-induced arthritis in mice.","date":"2006","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16542376","citation_count":17,"is_preprint":false},{"pmid":"35573728","id":"PMC_35573728","title":"Novel Disease-Associated Missense Single-Nucleotide Polymorphisms Variants Predication by Algorithms Tools and Molecular Dynamics Simulation of Human TCIRG1 Gene Causing Congenital Neutropenia and Osteopetrosis.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/35573728","citation_count":17,"is_preprint":false},{"pmid":"22245629","id":"PMC_22245629","title":"Murine ameloblasts are immunonegative for Tcirg1, the v-H-ATPase subunit essential for the osteoclast plasma proton pump.","date":"2012","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/22245629","citation_count":16,"is_preprint":false},{"pmid":"20665709","id":"PMC_20665709","title":"OC-116, the chicken ortholog of mammalian MEPE found in eggshell, is also expressed in bone cells.","date":"2010","source":"Journal of experimental zoology. Part B, Molecular and developmental evolution","url":"https://pubmed.ncbi.nlm.nih.gov/20665709","citation_count":16,"is_preprint":false},{"pmid":"27541021","id":"PMC_27541021","title":"Regulation and Function of Lentiviral Vector-Mediated TCIRG1 Expression in Osteoclasts from Patients with Infantile Malignant Osteopetrosis: Implications for Gene Therapy.","date":"2016","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/27541021","citation_count":14,"is_preprint":false},{"pmid":"15809087","id":"PMC_15809087","title":"Identification of new alternative splice events in the TCIRG1 gene in different human tissues.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15809087","citation_count":14,"is_preprint":false},{"pmid":"31111556","id":"PMC_31111556","title":"Novel c.G630A TCIRG1 mutation causes aberrant splicing resulting in an unusually mild form of autosomal recessive osteopetrosis.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31111556","citation_count":13,"is_preprint":false},{"pmid":"27229898","id":"PMC_27229898","title":"Association Between Absolute Neutrophil Count and Variation at TCIRG1: The NHLBI Exome Sequencing Project.","date":"2016","source":"Genetic epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/27229898","citation_count":13,"is_preprint":false},{"pmid":"32790690","id":"PMC_32790690","title":"Knockdown of Tcirg1 inhibits large-osteoclast generation by down-regulating NFATc1 and IP3R2 expression.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32790690","citation_count":12,"is_preprint":false},{"pmid":"18270567","id":"PMC_18270567","title":"HLA-DR alpha 2 mediates negative signalling via binding to Tirc7 leading to anti-inflammatory and apoptotic effects in lymphocytes in vitro and in vivo.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18270567","citation_count":12,"is_preprint":false},{"pmid":"17138060","id":"PMC_17138060","title":"TIRC7 is induced in rejected human kidneys and anti-TIRC7 mAb with FK506 prolongs survival of kidney allografts in rats.","date":"2006","source":"Transplant immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17138060","citation_count":12,"is_preprint":false},{"pmid":"31938717","id":"PMC_31938717","title":"Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis.","date":"2020","source":"Bone reports","url":"https://pubmed.ncbi.nlm.nih.gov/31938717","citation_count":12,"is_preprint":false},{"pmid":"23412864","id":"PMC_23412864","title":"A case of autosomal dominant osteopetrosis type II with a novel TCIRG1 gene mutation.","date":"2013","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/23412864","citation_count":12,"is_preprint":false},{"pmid":"31567691","id":"PMC_31567691","title":"TCIRG1 Transgenic Rescue of Osteoclast Function Using Induced Pluripotent Stem Cells Derived from Patients with Infantile Malignant Autosomal Recessive Osteopetrosis.","date":"2019","source":"The Journal of bone and joint surgery. American volume","url":"https://pubmed.ncbi.nlm.nih.gov/31567691","citation_count":11,"is_preprint":false},{"pmid":"21472218","id":"PMC_21472218","title":"Fluid shear stress changes cell morphology and regulates the expression of ATP6V1A and TCIRG1 mRNA in rat osteoclasts.","date":"2010","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/21472218","citation_count":10,"is_preprint":false},{"pmid":"24898387","id":"PMC_24898387","title":"Epiregulin (EREG) and human V-ATPase (TCIRG1): genetic variation, ethnicity and pulmonary tuberculosis susceptibility in Guinea-Bissau and The Gambia.","date":"2014","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24898387","citation_count":10,"is_preprint":false},{"pmid":"30898715","id":"PMC_30898715","title":"TCIRG1 and SNX10 gene mutations in the patients with autosomal recessive osteopetrosis.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30898715","citation_count":9,"is_preprint":false},{"pmid":"24535484","id":"PMC_24535484","title":"Identification of TCIRG1 and CLCN7 gene mutations in a patient with autosomal recessive osteopetrosis.","date":"2014","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/24535484","citation_count":9,"is_preprint":false},{"pmid":"21042819","id":"PMC_21042819","title":"Novel mutation of TCIRG1 and clinical pictures of two infantile malignant osteopetrosis patients.","date":"2010","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21042819","citation_count":9,"is_preprint":false},{"pmid":"30084437","id":"PMC_30084437","title":"Autosomal recessive osteopetrosis type I: description of pathogenic variant of TCIRG1 gene.","date":"2018","source":"Boletin medico del Hospital Infantil de Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/30084437","citation_count":9,"is_preprint":false},{"pmid":"18715141","id":"PMC_18715141","title":"Characterization of a novel Alu-Alu recombination-mediated genomic deletion in the TCIRG1 gene in five osteopetrotic patients.","date":"2009","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/18715141","citation_count":9,"is_preprint":false},{"pmid":"15883619","id":"PMC_15883619","title":"TIRC7 pathway as a target for preventing allograft rejection.","date":"2005","source":"Drug news & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/15883619","citation_count":7,"is_preprint":false},{"pmid":"37599332","id":"PMC_37599332","title":"Atp6i deficient mouse model uncovers transforming growth factor-β1 /Smad2/3 as a key signaling pathway regulating odontoblast differentiation and tooth root formation.","date":"2023","source":"International journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/37599332","citation_count":7,"is_preprint":false},{"pmid":"24989235","id":"PMC_24989235","title":"A founder mutation in the TCIRG1 gene causes osteopetrosis in the Ashkenazi Jewish population.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24989235","citation_count":7,"is_preprint":false},{"pmid":"28844534","id":"PMC_28844534","title":"Eggshell matrix proteins OC-116, OC-17 and OCX36 in hen's sperm storage tubules.","date":"2017","source":"Animal reproduction science","url":"https://pubmed.ncbi.nlm.nih.gov/28844534","citation_count":7,"is_preprint":false},{"pmid":"12687885","id":"PMC_12687885","title":"Osteoclast morphology in autosomal recessive malignant osteopetrosis due to a TCIRG1 gene mutation.","date":"2003","source":"Pediatric pathology & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12687885","citation_count":7,"is_preprint":false},{"pmid":"30539151","id":"PMC_30539151","title":"Ophthalmic phenotype of TCIRG1 gene mutations in Chinese infantile malignant osteopetrosis.","date":"2018","source":"BMJ open ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/30539151","citation_count":6,"is_preprint":false},{"pmid":"38261998","id":"PMC_38261998","title":"Autosomal Dominant Osteopetrosis (ADO) Caused by a Missense Variant in the TCIRG1 Gene.","date":"2024","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38261998","citation_count":6,"is_preprint":false},{"pmid":"31794943","id":"PMC_31794943","title":"Generation of 3 clones of induced pluripotent stem cells (iPSCs) from a patient affected by Autosomal Recessive Osteopetrosis due to mutations in TCIRG1 gene.","date":"2019","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31794943","citation_count":6,"is_preprint":false},{"pmid":"32319655","id":"PMC_32319655","title":"TIRC7 inhibits Th1 cells by upregulating the expression of CTLA‑4 and STAT3 in mice with acute graft‑versus‑host disease.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32319655","citation_count":5,"is_preprint":false},{"pmid":"30431110","id":"PMC_30431110","title":"CLCN7 and TCIRG1 mutations in a single family: Evidence for digenic inheritance of osteopetrosis.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30431110","citation_count":5,"is_preprint":false},{"pmid":"24526664","id":"PMC_24526664","title":"TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis.","date":"2014","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24526664","citation_count":4,"is_preprint":false},{"pmid":"22280207","id":"PMC_22280207","title":"A novel TCIRG1 gene mutation leads to severe osteopetrosis with altered content of monocytes/macrophages in several organs.","date":"2012","source":"Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society","url":"https://pubmed.ncbi.nlm.nih.gov/22280207","citation_count":4,"is_preprint":false},{"pmid":"28604959","id":"PMC_28604959","title":"[Analysis of TCIRG1 gene mutation in a Chinese family affected with infantile malignant osteopetrosis].","date":"2017","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28604959","citation_count":3,"is_preprint":false},{"pmid":"40995561","id":"PMC_40995561","title":"Tcirg1 deficiency delays osteoarthritis progression by impairing lysosome acidification and peripheral accumulation in osteoclasts.","date":"2025","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/40995561","citation_count":2,"is_preprint":false},{"pmid":"22015593","id":"PMC_22015593","title":"Monocytes differentiation upon treatment with a peptide corresponding to the C-terminus of activated T cell-expressed Tirc7 protein.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22015593","citation_count":2,"is_preprint":false},{"pmid":"29723947","id":"PMC_29723947","title":"[Identification of new mutations in TCIRG1 as a cause of infantile malignant osteopetrosis in two Mexican patients].","date":"2018","source":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/29723947","citation_count":2,"is_preprint":false},{"pmid":"34210262","id":"PMC_34210262","title":"Two novel mutations in TCIRG1 induced infantile malignant osteopetrosis: a case report.","date":"2021","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34210262","citation_count":1,"is_preprint":false},{"pmid":"40964614","id":"PMC_40964614","title":"Modeling TCIRG1 Neutropenia by Utilizing Patient Derived Induced Pluripotent Stem Cells.","date":"2025","source":"Journal of cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40964614","citation_count":1,"is_preprint":false},{"pmid":"37107657","id":"PMC_37107657","title":"Outlining the Clinical Profile of TCIRG1 14 Variants including 5 Novels with Overview of ARO Phenotype and Ethnic Impact in 20 Egyptian Families.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/37107657","citation_count":1,"is_preprint":false},{"pmid":"41673363","id":"PMC_41673363","title":"Single-Cell Multiomics Decoding of TCIRG1-Mediated Cuproptosis Circuitry Rewiring Immune-Metabolic Landscape in Ischemic Stroke.","date":"2026","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/41673363","citation_count":0,"is_preprint":false},{"pmid":"42193285","id":"PMC_42193285","title":"Clinical and Molecular Characterization of TCIRG1-Related Autosomal Recessive Osteopetrosis with Current Therapeutic Approaches.","date":"2026","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/42193285","citation_count":0,"is_preprint":false},{"pmid":"39267677","id":"PMC_39267677","title":"VMA21: unveiling a novel oncogene that facilitates immune evasion in triple-negative breast cancer through TCIRG1 protein stability regulation.","date":"2024","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39267677","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38805,"output_tokens":7071,"usd":0.11124,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16188,"output_tokens":5492,"usd":0.10912,"stage2_stop_reason":"end_turn"},"total_usd":0.22036,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Targeted disruption of Atp6i (TCIRG1/a3 subunit of vacuolar proton pump) in mice results in severe osteopetrosis. Atp6i-/- osteoclast-like cells lose extracellular acidification function but retain intracellular lysosomal proton pump activity. pH in Atp6i-/- liver lysosomes and proton transport in microsomes of Atp6i-/- kidney are identical to wild-type, demonstrating that Atp6i is uniquely and specifically required for osteoclast-mediated extracellular acidification.\",\n      \"method\": \"Targeted gene disruption (knockout mouse), extracellular acidification assay, lysosomal pH measurement, microsome proton transport assay\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — clean knockout with multiple orthogonal functional assays demonstrating compartment-specific proton pump requirement\",\n      \"pmids\": [\"10581033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TCIRG1, encoding the osteoclast-specific 116-kDa subunit (a3) of the vacuolar proton pump, is mutated in human autosomal recessive osteopetrosis patients. Osteoclasts are present in normal or elevated numbers, indicating the defect is in functional capacity (acidification) rather than osteoclast differentiation.\",\n      \"method\": \"Mutation analysis (DNA sequencing), patient cohort genotyping\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic causation established in human patients, replicated across multiple labs and extended in subsequent studies\",\n      \"pmids\": [\"10888887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In vitro-differentiated osteoclasts from TCIRG1 compound heterozygous patients attach to bone and undergo cell fusion but fail to acidify attachment sites, consistent with TCIRG1 being essential for H+-ATPase assembly at the ruffled border. CLCN7-deficient osteoclasts, by contrast, do secrete acid but have defective organic matrix removal, distinguishing the two proteins' roles.\",\n      \"method\": \"In vitro osteoclast differentiation from CD14+ monocytes, acid secretion assay, bone pitting assay, enzyme assays, attachment protein assays\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional assays on patient-derived cells with genotype correlation, multiple orthogonal readouts\",\n      \"pmids\": [\"15231021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Bone biopsies from TCIRG1-mutant osteopetrosis patients show osteoclasts that are morphologically normal (actin rings, clear zones, podosomes, normal alphavbeta3, c-Src, PYK2) and TRAP-positive, but are a3-subunit-negative and excavate only faint, shallow pits, indicating inefficient bone resorption due to absent proton pump subunit. Post-bone marrow transplant osteoclasts rescue a3 subunit immunoreactivity.\",\n      \"method\": \"Bone biopsy analysis, immunohistochemistry, in vitro osteoclast differentiation, bone resorption pit assay, TRAP activity assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional and morphological characterization of patient osteoclasts with genotype-phenotype correlation and transplant rescue\",\n      \"pmids\": [\"12507890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Electron microscopy of bone biopsies from a TCIRG1-mutant osteopetrosis infant showed osteoclasts lacking ruffled borders. Post-transplant donor osteoclasts had ruffled borders and intracytoplasmic mineral crystals, demonstrating active bone resorption restored by donor TCIRG1-expressing osteoclasts.\",\n      \"method\": \"Electron microscopy of bone biopsies pre- and post-bone marrow transplantation\",\n      \"journal\": \"Pediatric pathology & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — electron microscopy with transplant rescue, single case report\",\n      \"pmids\": [\"12687885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TIRC7 (an alternative transcript product of the TCIRG1 locus) functions as a membrane protein essential for T cell activation. Anti-TIRC7 antibodies prevent human T cell proliferation and IL-2 secretion in vitro, specifically inhibit IFN-gamma (Th1) but not IL-4 (Th2) expression, and prolong kidney allograft survival in vivo via inhibition of rat alloimmune response.\",\n      \"method\": \"In vitro T cell proliferation assay, cytokine secretion assay, rat kidney allograft transplantation model, anti-TIRC7 antibody modulation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro and in vivo functional experiments with antibody intervention, replicated across multiple subsequent studies\",\n      \"pmids\": [\"9806637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TIRC7 and OC116 (TCIRG1) are alternative transcripts of the same gene on chromosome 11q13.4-q13.5, with TIRC7 consisting of 15 exons and OC116 of 20 exons sharing the last 14 introns and exons. In human alloactivated T lymphocytes, only TIRC7 (not OC116) mRNA is expressed, indicating transcript-specific expression patterns.\",\n      \"method\": \"Genomic cloning, exon-intron boundary analysis, RT-PCR in alloactivated T lymphocytes\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct genomic characterization with functional validation of differential expression; confirmed by multiple subsequent studies\",\n      \"pmids\": [\"10329006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TIRC7-deficient (knockout) mice exhibit increased T and B cell proliferation, elevated IL-2, IFN-gamma, and IL-4, expansion of memory/effector T cells (decreased CD62L, increased CD11a/CD44), decreased CTLA-4 expression in activated T cells, B cell hyperreactivity, and augmented delayed-type hypersensitivity. This establishes TIRC7 as a negative regulator of both T and B cell responses.\",\n      \"method\": \"Gene targeting (knockout mouse), in vitro T and B cell proliferation assays, cytokine expression assays, flow cytometry, delayed-type hypersensitivity model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout mouse with multiple orthogonal in vitro and in vivo functional readouts\",\n      \"pmids\": [\"15294947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Anti-TIRC7 antibody targeting induces early cell surface expression of CTLA-4. TIRC7 co-localizes with CTLA-4 and both accumulate at the site of antigen adhesion upon T cell activation. Both are associated with clathrin-coated vesicles, indicating shared intracellular transport. Anti-TIRC7-mediated inhibition of T cell proliferation is abolished by anti-CTLA-4 antibody blockade, and CTLA-4-deficient mouse splenocytes are not responsive to TIRC7 antibody. Thus TIRC7 acts upstream of CTLA-4.\",\n      \"method\": \"Flow cytometry, immunofluorescence co-localization, CTLA-4 transcription activation assay, anti-CTLA-4 blockade rescue experiments, CTLA-4 knockout mouse splenocytes\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods establishing epistatic relationship between TIRC7 and CTLA-4, including genetic rescue with CTLA-4 KO\",\n      \"pmids\": [\"17082597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HLA-DR alpha2 domain (sHLA-DRalpha2) binds TIRC7 on lymphocytes, inducing negative signaling: inhibition of proliferation, apoptosis of CD4+ and CD8+ T cells via intrinsic pathway, SHP-1 recruitment by TIRC7, decreased phosphorylation of STAT4, TCR-zeta chain and ZAP70, inhibition of IFN-gamma and FasL. HLA-DRalpha2 and TIRC7 co-localize at the APC-T cell interaction site.\",\n      \"method\": \"Co-localization by microscopy, SHP-1 recruitment assay, phosphorylation assays (STAT4, TCR-zeta, ZAP70), cytokine expression assays, apoptosis assays, LPS stimulation in vitro, in vivo apoptosis assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — binding partner identified, downstream signaling cascade characterized with multiple orthogonal methods\",\n      \"pmids\": [\"18270567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In Tcirg1-/- (a3-deficient) mice, the a3 subunit accumulates in the choriocapillary meshwork in uveal tissues, while a4 subunit expression is increased in the choriocapillary meshwork of mutant mice (compensatory upregulation). Narrowed foramina in the skull (demonstrated by X-ray microtomography) cause optic nerve compression with increased retinal apoptosis, despite normal retinal architecture.\",\n      \"method\": \"X-ray microtomography, immunohistochemistry for V-ATPase subunit localization, apoptosis assay (retina), Tcirg1-/- mice\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct localization and functional consequence in KO mice, single study with multiple methods but limited replication\",\n      \"pmids\": [\"20711468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Murine maturation-stage ameloblasts are immunonegative for Tcirg1 (a3 subunit), despite expressing V-ATPase subunit b (brain isoform). In Tcirg1 null (oc/oc) mice, enamel formation is normal and ameloblasts are unaffected, demonstrating that the a3 subunit is not required for ameloblast proton pump activity and that a different V-ATPase isoform functions there.\",\n      \"method\": \"Immunohistochemistry, Tcirg1 null mouse analysis, enamel mineral content analysis\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct immunolocalization and functional characterization in KO mice, single study\",\n      \"pmids\": [\"22245629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lentiviral gene transfer of TCIRG1 into peripheral blood CD34+ cells from TCIRG1-deficient osteopetrosis patients restored osteoclast resorptive function in vitro, as measured by increased Ca2+ release, CTX-I bone degradation product, and resorption pit formation on bone slices. Non-corrected patient osteoclasts failed to resorb bone.\",\n      \"method\": \"Lentiviral gene transfer, in vitro osteoclast differentiation on bone slices, qPCR, western blot, Ca2+ release assay, CTX-I ELISA, resorption pit assay, NSG mouse engraftment\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gene correction with multiple functional readouts, multiple patient samples, in vivo engraftment demonstrated\",\n      \"pmids\": [\"23907031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"AAV-mediated RNAi knockdown of Atp6i/TIRC7 in periodontal tissues impairs extracellular acidification and osteoclast-mediated bone resorption, protecting mice from P. gingivalis infection-stimulated bone loss (>85% reduction) and decreasing T-cell infiltration. Atp6i haploinsufficient mice (Atp6i+/-) show similar protection from bone resorption and inflammation.\",\n      \"method\": \"AAV-shRNA knockdown in vivo, P. gingivalis infection model, bone resorption measurement, T-cell quantification, cytokine gene expression analysis, Atp6i+/- haploinsufficiency comparison\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gene knockdown and haploinsufficiency model with multiple orthogonal readouts\",\n      \"pmids\": [\"23577057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"AAV-mediated Atp6i RNAi knockdown in periapical tissues inhibits osteoclast function in vitro and in vivo, reduces T-cell numbers in periapical lesions, and reduces bacterial infection-stimulated periapical bone resorption by ~80%. Atp6i+/- haploinsufficient mice show similar protection.\",\n      \"method\": \"AAV-shRNA knockdown, endodontic disease mouse model, in vitro osteoclast function assay, T-cell quantification, bone resorption measurement\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gene knockdown with haploinsufficiency confirmation and multiple functional readouts\",\n      \"pmids\": [\"23166162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TCIRG1 mutations cause severe osteoid accumulation (osteomalacia) in osteopetrosis patients, whereas CLCN7 and TNFRSF11A mutations do not. Undecalcified bone biopsies from TCIRG1-mutant patients show pathological osteoid increase and decreased calcium content in mineralized matrix, revealing a specific role of TCIRG1/a3-mediated acidification in bone matrix mineralization.\",\n      \"method\": \"Undecalcified iliac crest bone biopsy histology, quantitative bone histomorphometry, serum calcium measurement\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct bone histology in multiple patients with genotype-phenotype comparison across three gene groups\",\n      \"pmids\": [\"24108692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TCIRG1 heterozygous mutations (including R736S, identified in a large pedigree) cause severe congenital neutropenia with reduced TCIRG1 protein levels in affected individuals (western blot). This establishes that TCIRG1 dysfunction impairs not only osteoclast but also neutrophil function.\",\n      \"method\": \"Western blot (reduced protein in affected individuals), family segregation analysis, DNA sequencing\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — protein reduction confirmed by western blot, perfect family cosegregation, but mechanistic detail is limited\",\n      \"pmids\": [\"24753205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Lentiviral vector-mediated TCIRG1 expression in osteoclasts is post-transcriptionally regulated, being detected only in mature osteoclasts (not precursors or macrophages) despite GFP being expressed in all cell types from the same bicistronic vector. Codon optimization increases mRNA but decreases protein levels and functional rescue. Addition of 30% wild-type CD34+ cells to TCIRG1-deficient cells is sufficient to completely normalize resorptive function in vitro.\",\n      \"method\": \"Lentiviral gene transfer, qPCR, western blot, in vitro osteoclast differentiation, resorption assay, GFP reporter comparison\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple assays in a single study establishing post-transcriptional regulation mechanism and functional threshold\",\n      \"pmids\": [\"27541021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A novel TCIRG1 mutation (c.G630A) causes aberrant splicing producing exon 5-6 deletion (ΔE56). The ΔE56-truncated protein (lacking part of the cytoplasmic N-terminal domain) fails to complement V-ATPase function in yeast (fails to grow on Zn2+-containing plates requiring vacuolar acidification), while the full-length protein does. This demonstrates the N-terminal cytoplasmic domain (encoded by exons 5-6) is required for V-ATPase function.\",\n      \"method\": \"Splice assay, yeast complementation assay (Vph1p ortholog), in vitro osteoclast differentiation from patient monocytes, bone resorption pit assay, TCIRG1 protein/mRNA expression analysis\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — yeast reconstitution assay combined with patient cell functional assays and mutation characterization\",\n      \"pmids\": [\"31111556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCIRG1 transgenic expression in iPSC-derived osteoclasts from a compound heterozygous TCIRG1 patient restored bone-resorbing function (pit formation), and also rescued reduced expression of cathepsin K (CTSK) and tartrate-resistant acid phosphatase (TRAP). This demonstrates that TCIRG1 loss reduces not only proton pump activity but also expression of downstream bone remodeling enzymes.\",\n      \"method\": \"iPSC generation and osteoclast differentiation, transgenic TCIRG1 expression, pit formation assay, gene expression analysis (CTSK, TRAP), western blot\",\n      \"journal\": \"The Journal of bone and joint surgery. American volume\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — iPSC-derived osteoclasts with transgenic rescue, multiple functional readouts, single study\",\n      \"pmids\": [\"31567691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Knockdown of Tcirg1 in mouse bone marrow-derived monocytes inhibits large osteoclast (>100 μm) generation by decreasing expression of NFATc1 and IP3R2. Reduced IP3R2 lowers intracellular calcium levels, which limits nuclear translocation of NFATc1 in RANKL-induced osteoclastogenesis.\",\n      \"method\": \"Lentiviral Tcirg1 knockdown in BMMs, osteoclast differentiation assay, NFATc1/IP3R2 expression analysis, intracellular calcium measurement, nuclear translocation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with mechanistic pathway characterization (NFATc1/IP3R2/Ca2+), single lab study\",\n      \"pmids\": [\"32790690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Atp6i-/- (TCIRG1-deficient) mice exhibit arrested tooth root formation with truncated Hertwig's epithelial root sheath progression and reduced odontoblast differentiation. Conditioned medium from wild-type osteoclasts (but not Atp6i-/- osteoclasts) promotes odontoblast differentiation via TGF-β1/Smad2/3 signaling. Anti-TGF-β1 neutralization blocks this effect. Ectopic TGF-β1 partially rescues root development in Atp6i-/- tooth germ transplants, establishing TGF-β1 release from bone matrix (dependent on TCIRG1-mediated osteoclast acidification) as a key pathway for odontoblast differentiation and tooth root formation.\",\n      \"method\": \"Atp6i-/- mouse analysis, conditioned medium experiments, anti-TGF-β1 neutralization, Smad2/3 activation assay, RNA-seq, kidney capsule tooth germ transplant rescue, immunohistochemistry\",\n      \"journal\": \"International journal of oral science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including KO mouse, conditioned medium, neutralization, and in vivo rescue experiments establishing TGF-β1/Smad2/3 pathway downstream of TCIRG1\",\n      \"pmids\": [\"37599332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Tcirg1 deficiency in osteoclasts impairs lysosome acidification and peripheral (plasma membrane) accumulation of lysosomes, thereby inhibiting osteoclast fusion and bone resorption. Tcirg1-knockout mice show delayed OA progression with reduced subchondral bone loss and cartilage damage.\",\n      \"method\": \"Tcirg1 knockout mouse OA model (destabilization of medial meniscus), histology, micro-CT, in vitro osteoclast differentiation assay, lysosome acidification assay, lysosome distribution analysis\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with in vitro mechanistic follow-up on lysosome biology, single lab study\",\n      \"pmids\": [\"40995561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CRISPR/Cas9-mediated correction of the R736C TCIRG1 mutation in patient-derived iPSCs restored normal neutrophil differentiation. Mutant iPSC lines showed reduced TCIRG1 protein expression and altered intracellular localization (more diffuse cytosolic distribution), suggesting structural and functional disruption of the V-ATPase complex underlies impaired granulopoiesis.\",\n      \"method\": \"iPSC generation from patients, CRISPR/Cas9 correction, in vitro hematopoietic differentiation, immunofluorescence for TCIRG1 localization, proliferation and survival assays\",\n      \"journal\": \"Journal of cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR rescue with localization and functional assays, single lab study\",\n      \"pmids\": [\"40964614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VMA21 binds TCIRG1 protein and inhibits its ubiquitination-mediated degradation, thereby stabilizing TCIRG1 protein expression in triple-negative breast cancer cells. VMA21 knockdown reduces TCIRG1 protein levels and impairs TNBC cell proliferation, invasion, and immune evasion.\",\n      \"method\": \"Immunoprecipitation (VMA21-TCIRG1 interaction), ubiquitination assay, VMA21 knockdown, western blot, cell proliferation/invasion/migration assays, CD8+ T cell co-culture assay\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and ubiquitination assay establish interaction and regulatory mechanism, single lab study in cancer context\",\n      \"pmids\": [\"39267677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The C-terminal extracellular peptide of Tirc7 (the T-cell-expressed TCIRG1 transcript) induces differentiation of RAW264.7 cells and mouse bone marrow CD11b+ cells into osteoclast-like multinucleated TRACP-positive cells, and induces an autocrine/paracrine regulatory loop in osteoclast precursors. Primary monocytes treated with Tirc7-Cter peptide form small multinucleated cells with dendritic cell marker modulation but lacking resorbing activity.\",\n      \"method\": \"Molecular cloning of Tirc7 C-terminal peptide, treatment of RAW264.7 and bone marrow-derived precursor cells, TRACP staining, F4/80 expression analysis, resorption activity assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, peptide-based experiment with partial mechanistic follow-up, no genetic confirmation\",\n      \"pmids\": [\"22015593\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TCIRG1 encodes the a3 subunit of the vacuolar H+-ATPase (V-ATPase), which is essential for osteoclast-mediated extracellular acidification at the bone resorption lacuna (ruffled border); loss of TCIRG1 specifically abolishes extracellular acidification while preserving intracellular lysosomal V-ATPase activity, causing severe osteopetrosis. The same gene locus produces an alternative transcript (TIRC7) in T lymphocytes that negatively regulates T and B cell activation by acting upstream of CTLA-4 (inducing its surface expression and transcription) and by transducing inhibitory signals upon engagement by HLA-DR alpha2 via SHP-1 recruitment and reduced STAT4/ZAP70/TCR-zeta phosphorylation. In osteoclasts, TCIRG1 also regulates lysosome acidification and peripheral lysosome accumulation required for osteoclast fusion and bone resorption, controls NFATc1 nuclear translocation via IP3R2-dependent calcium oscillations, and enables TGF-β1 release from bone matrix that drives odontoblast differentiation via Smad2/3 signaling; TCIRG1 protein stability in cancer cells is regulated by VMA21, which prevents its ubiquitination-mediated degradation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TCIRG1 encodes the osteoclast-specific 116-kDa a3 subunit of the vacuolar H+-ATPase (V-ATPase), and is uniquely required for osteoclast-mediated extracellular acidification at the bone-resorption surface while being dispensable for intracellular lysosomal proton-pump activity in other tissues [#0]. Loss of TCIRG1 causes severe autosomal recessive osteopetrosis in humans: osteoclasts are present in normal or elevated numbers and attach to bone with intact actin rings and podosomes, but lack ruffled borders, fail to acidify their attachment sites, and excavate only shallow pits — establishing the defect as functional rather than developmental [#1, #2, #3]. The a3 N-terminal cytoplasmic domain (encoded by exons 5–6) is required for V-ATPase function, as the corresponding truncation fails to complement vacuolar acidification in yeast [#18]. Beyond proton transport per se, TCIRG1-dependent acidification drives downstream osteoclast biology: it controls lysosome acidification and peripheral lysosome accumulation needed for cell fusion and resorption [#22], supports NFATc1 nuclear translocation through IP3R2-dependent calcium signaling during RANKL-induced osteoclastogenesis [#20], enables release of matrix TGF-β1 that drives odontoblast differentiation and tooth-root formation via Smad2/3 signaling [#21], and is required for matrix mineralization, with TCIRG1 mutation producing osteoid accumulation not seen with CLCN7 or TNFRSF11A defects [#15]. Restoration of TCIRG1 by lentiviral, transgenic, or CRISPR-corrected approaches rescues resorptive function and downstream enzyme expression (cathepsin K, TRAP) in patient-derived osteoclasts [#12, #19]. The same locus produces an alternative transcript, TIRC7, expressed in activated lymphocytes rather than the osteoclast OC116 form [#6]; TIRC7 acts as a negative regulator of T and B cell activation, functioning upstream of CTLA-4 to induce its expression and transducing inhibitory signals upon engagement by HLA-DR alpha2 via SHP-1 recruitment and reduced STAT4/ZAP70/TCR-zeta phosphorylation [#7, #8, #9]. TCIRG1 mutations also cause severe congenital neutropenia through impaired neutrophil/granulopoiesis function [#16, #23], and TCIRG1 protein in cancer cells is stabilized by VMA21, which blocks its ubiquitination-mediated degradation [#24].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved whether the a3 subunit serves a general or compartment-specific proton-pump role, showing it is uniquely required for osteoclast extracellular acidification but not lysosomal acidification elsewhere.\",\n      \"evidence\": \"Atp6i knockout mice with extracellular acidification, lysosomal pH, and microsome proton-transport assays\",\n      \"pmids\": [\"10581033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify which alternative a-subunit isoforms maintain lysosomal V-ATPase activity in TCIRG1-null cells\", \"Molecular basis for the osteoclast-specific requirement not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Established TCIRG1 as a genetic cause of human autosomal recessive osteopetrosis, localizing the defect to osteoclast acidification capacity rather than osteoclast number.\",\n      \"evidence\": \"Mutation analysis and genotyping of human osteopetrosis patient cohort\",\n      \"pmids\": [\"10888887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish the structural consequence of individual mutations\", \"Fraction of osteopetrosis attributable to TCIRG1 versus other loci not addressed here\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed that TCIRG1-deficient osteoclasts complete attachment and fusion but fail to acidify and form ruffled borders, distinguishing the TCIRG1 acidification defect from the matrix-degradation defect of CLCN7.\",\n      \"evidence\": \"Patient-derived in vitro osteoclasts, bone biopsies, immunohistochemistry, EM, acid-secretion and pit assays, with transplant rescue\",\n      \"pmids\": [\"15231021\", \"12507890\", \"12687885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define how the a3 subunit is targeted to and assembled at the ruffled border\", \"Mechanism linking acidification loss to ruffled-border absence not resolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified TIRC7 as a lymphocyte-expressed product of the TCIRG1 locus essential for T cell activation, with antibody targeting selectively suppressing Th1 responses and prolonging allograft survival.\",\n      \"evidence\": \"Anti-TIRC7 antibody modulation in human T cell proliferation/cytokine assays and a rat kidney allograft model\",\n      \"pmids\": [\"9806637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Antibody-based readouts do not define the endogenous ligand or receptor partner at this stage\", \"Relationship of TIRC7 to the osteoclast a3 protein not yet established\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated that TIRC7 and OC116/TCIRG1 are alternative transcripts of one locus with tissue-restricted expression, explaining how a single gene yields both an immune regulator and an osteoclast proton-pump subunit.\",\n      \"evidence\": \"Genomic cloning, exon-intron mapping, and RT-PCR in alloactivated T lymphocytes\",\n      \"pmids\": [\"10329006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional control of the isoform switch not defined\", \"Whether the two protein products share any functional domains in their respective contexts not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Established TIRC7 as a negative regulator of both T and B cell responses through loss-of-function genetics, linking it to control of CTLA-4 expression and memory/effector differentiation.\",\n      \"evidence\": \"TIRC7 knockout mice with proliferation, cytokine, flow-cytometry and delayed-type hypersensitivity assays\",\n      \"pmids\": [\"15294947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish the molecular signaling intermediates downstream of TIRC7\", \"Mechanism connecting TIRC7 to CTLA-4 not yet defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed TIRC7 epistatically upstream of CTLA-4, showing it induces CTLA-4 surface expression and that its inhibitory action requires CTLA-4.\",\n      \"evidence\": \"Flow cytometry, immunofluorescence co-localization, anti-CTLA-4 blockade rescue, and CTLA-4 knockout splenocytes\",\n      \"pmids\": [\"17082597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the receptor/ligand that triggers TIRC7 signaling\", \"Mechanism of clathrin-coated-vesicle co-trafficking with CTLA-4 not detailed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified HLA-DR alpha2 as a TIRC7 binding partner that triggers an inhibitory signaling cascade, defining the receptor-proximal mechanism of TIRC7-mediated lymphocyte suppression.\",\n      \"evidence\": \"Co-localization, SHP-1 recruitment, phospho-STAT4/TCR-zeta/ZAP70 assays, apoptosis and cytokine assays\",\n      \"pmids\": [\"18270567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of the HLA-DRalpha2–TIRC7 interaction not resolved\", \"How a V-ATPase-related transcript transduces a phosphatase-recruiting signal mechanistically unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated therapeutic restorability of osteoclast function and showed Atp6i targeting protects against infection-driven bone loss, validating TCIRG1 acidification as both a corrigible defect and a drug target.\",\n      \"evidence\": \"Lentiviral TCIRG1 gene transfer into patient CD34+ cells with resorption readouts; AAV-RNAi knockdown and haploinsufficiency in periodontal and periapical infection models\",\n      \"pmids\": [\"23907031\", \"23577057\", \"23166162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define the minimal expression level for durable in vivo correction\", \"Whether reduced T-cell infiltration is a direct or secondary consequence of acidification loss not separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Expanded the TCIRG1 phenotypic spectrum to matrix mineralization and to neutrophil biology, showing TCIRG1 loss causes osteoid accumulation distinct from other osteopetrosis genes and underlies a form of severe congenital neutropenia.\",\n      \"evidence\": \"Undecalcified bone histomorphometry across gene groups; family segregation with western-blot confirmation of reduced TCIRG1 protein\",\n      \"pmids\": [\"24108692\", \"24753205\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking acidification to mineralization versus osteoid build-up not resolved\", \"How heterozygous TCIRG1 dysfunction specifically impairs granulopoiesis not mechanistically defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped a required functional element to the exon 5–6-encoded N-terminal cytoplasmic domain and confirmed transgenic rescue, connecting a specific splice/structural defect to loss of V-ATPase activity.\",\n      \"evidence\": \"Splice assay, yeast Vph1p complementation, and TCIRG1 transgenic rescue in iPSC-derived patient osteoclasts with enzyme-expression readouts\",\n      \"pmids\": [\"31111556\", \"31567691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full domain architecture and assembly requirements of the a3 subunit not delineated\", \"Why TCIRG1 loss reduces downstream CTSK/TRAP expression not mechanistically explained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked TCIRG1 to an osteoclastogenic signaling axis, showing its loss reduces IP3R2-dependent calcium and NFATc1 nuclear translocation, implicating TCIRG1 in regulation beyond direct proton transport.\",\n      \"evidence\": \"Lentiviral Tcirg1 knockdown in BMMs with NFATc1/IP3R2 expression, calcium measurement, and nuclear-translocation assays\",\n      \"pmids\": [\"32790690\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study without genetic rescue of the calcium/NFATc1 phenotype\", \"Whether the effect is downstream of acidification loss or an independent function unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established TCIRG1-dependent osteoclast acidification as the upstream event releasing matrix TGF-β1 to drive odontoblast differentiation and tooth-root formation via Smad2/3.\",\n      \"evidence\": \"Atp6i knockout mice, conditioned-medium experiments, anti-TGF-β1 neutralization, Smad2/3 assays, and in vivo tooth-germ transplant rescue\",\n      \"pmids\": [\"37599332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of matrix TGF-β1 versus other osteoclast-derived factors not separated\", \"Direct demonstration that acidification per se liberates TGF-β1 not provided\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a post-translational regulator of TCIRG1, showing VMA21 stabilizes the protein by preventing its ubiquitination-mediated degradation in cancer cells.\",\n      \"evidence\": \"VMA21-TCIRG1 co-immunoprecipitation, ubiquitination assay, VMA21 knockdown with proliferation/invasion and CD8+ T cell co-culture assays\",\n      \"pmids\": [\"39267677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab Co-IP without reciprocal validation of the interaction interface\", \"Ubiquitin ligase responsible for TCIRG1 turnover not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Refined the cellular mechanism of TCIRG1 in osteoclast fusion and granulopoiesis, linking it to lysosome acidification/peripheral distribution and to proper TCIRG1 localization within the V-ATPase complex.\",\n      \"evidence\": \"Tcirg1 knockout mouse OA model with lysosome acidification/distribution assays; CRISPR correction of R736C in patient iPSCs with neutrophil differentiation and localization readouts\",\n      \"pmids\": [\"40995561\", \"40964614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab studies without orthogonal confirmation of the lysosome-distribution mechanism\", \"How mislocalized mutant TCIRG1 disrupts V-ATPase assembly structurally not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single locus coordinates expression of the osteoclast a3 V-ATPase subunit versus the immunoregulatory TIRC7 transcript, and how TIRC7 mechanistically couples to phosphatase-based inhibitory signaling, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of the a3 subunit within the assembled osteoclast V-ATPase\", \"Regulatory logic of the OC116/TIRC7 isoform switch undefined\", \"Mechanistic link between V-ATPase function and downstream NFATc1/TGF-β1 signaling not fully separated from acidification\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 2, 18]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 18]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 22]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 22]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 2, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 7, 8, 9]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [2, 15, 21]}\n    ],\n    \"complexes\": [\"vacuolar H+-ATPase (V-ATPase)\"],\n    \"partners\": [\"VMA21\", \"CTLA4\", \"HLA-DRA\", \"SHP-1\", \"IP3R2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}